The FDA granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen/Genmab), a tissue factor–directed antibody and microtubule inhibitor conjugate, for adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
“Once recurrent or metastatic cervical cancer progresses, there is a need for more options for these patients,” said Robert L. Coleman, MD, the chief scientific officer of US Oncology Research and lead investigator